Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 21;28(19):2076-2087.
doi: 10.3748/wjg.v28.i19.2076.

Mixed neuroendocrine-non-neuroendocrine neoplasms of the digestive system: A mini-review

Deepak Toor  1 , Jonathan M Loree  2 , Zu-Hua Gao  1 , Gang Wang  1 , Chen Zhou  1
Affiliations
Review

Mixed neuroendocrine-non-neuroendocrine neoplasms of the digestive system: A mini-review

Deepak Toor et al. World J Gastroenterol. .

Abstract

Mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs) are rare mixed tumors containing both neuroendocrine (NE) and non-NE components. Each component must occupy at least 30% of the tumor volume by definition. Recent molecular evidence suggests MiNENs are clonal neoplasms and potentially harbor targetable mutations similar to conventional carcinomas. There have been multiple changes in the nomenclature and classification of MiNENs which has created some confusion among pathologists on how to integrate the contributions of each component in a MiNEN, an issue which in turn has resulted in confusion in communication with front-line treating oncologists. This mini review summarizes our current understanding of MiNENs and outline diagnosis, prognosis, and management of these neoplasms. The authors emphasize the importance of treating the most aggressive component of the tumor regardless of its percentage volume.

Keywords: Mixed adenoneuorendocrine carcinoma; Mixed neuroendocrine neoplasms; Mixed neuroendocrine non-neuroendocrine neoplasms; Neuroendocrine; Non-neuroendocrine.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: JL has received consulting fees from Taiho, Ipsen, Novartis, Amgen, Eisai, and Bayer; research funding from Ipsen Biopharmaceuticals, Amgen, and Foundation Medicine.

Figures

Figure 1
Figure 1
Classification of mixed neuroendocrine neoplasms. Mixed neuroendocrine-non-neuroendocrine neoplasms are specific mixed neuroendocrine tumors, which show an intimate mixture of neuroendocrine and non-neuroendocrine cells and are both derived from a common precursor cell. MiNEN: Mixed neuroendocrine-non-neuroendocrine neoplasms.
Figure 2
Figure 2
Conceptual framework for mixed neuroendocrine-non-neuroendocrine neoplasm of the digestive system. The tumor must include one neuroendocrine component and one non-neuroendocrine component. In the digestive system both components must have metastatic potential, excluding benign non-neuroendocrine neoplasms such as adenomas or squamous papillomas. NET: Neuroendocrine tumors; NEC: Neuroendocrine carcinomas.
Figure 3
Figure 3
Evolution of the terminology of mixed neuroendocrine-non-neuroendocrine neoplasm. The terminology has been broadened to include other non-neuroendocrine epithelial components beyond adenocarcinoma as well as including indolent or benign tumors such as neuroendocrine tumors. NE: Neuroendocrine; NEC: Neuroendocrine carcinoma; NET: Neuroendocrine tumor; MEEC: Mixed exocrine-endocrine carcinoma; MANEC: Mixed adenoneuroendocrine carcinoma; MiNEN: Mixed neuroendocrine-non-neuroendocrine neoplasm.
Figure 4
Figure 4
Histopathology of a mixed neuroendocrine-non-neuroendocrine neoplasm of colon. A: Hematoxylin and eosin (H&E) stain of mixed neuroendocrine-non-neuroendocrine neoplasm. On the right side is a well-differentiated invasive adenocarcinoma. On the left side is a poorly differentiated neuroendocrine carcinoma (20 ×, H&E); B: The adenocarcinoma component is positive for cytokeratin 20, but the neuroendocrine component is negative (20 ×); C: Positive synaptophysin staining in the neuroendocrine component but negative staining in the adenocarcinoma component (20 ×); D: Positive CDX2 staining in both adenocarcinoma and neuroendocrine carcinoma components (20 ×); E: Merging area of adenocarcinoma and neuroendocrine carcinoma components (20 ×); F: Positive synaptophysin staining of neuroendocrine cells in the merged area (20 ×).
Figure 5
Figure 5
Sample pathology report. MiNEN: Mixed neuroendocrine-non-neuroendocrine neoplasm.
See this image and copyright information in PMC

References

    1. La Rosa S, Sessa F, Uccella S. Mixed Neuroendocrine-Nonneuroendocrine Neoplasms (MiNENs): Unifying the Concept of a Heterogeneous Group of Neoplasms. Endocr Pathol. 2016;27:284–311. - PubMed
    1. Frizziero M, Chakrabarty B, Nagy B, Lamarca A, Hubner RA, Valle JW, McNamara MG. Mixed Neuroendocrine Non-Neuroendocrine Neoplasms: A Systematic Review of a Controversial and Underestimated Diagnosis. J Clin Med. 2020;9 - PMC - PubMed
    1. Lokuhetty D, White VA, Watanabe R, Cree IA, World Health O, International Agency for Research on C. Digestive system tumours. Fifth ed. Lyon: International Agency for Research on Cancer, 2019.
    1. Lewin K. Carcinoid tumors and the mixed (composite) glandular-endocrine cell carcinomas. Am J Surg Pathol. 1987;11 Suppl 1:71–86. - PubMed
    1. Furlan D, Cerutti R, Genasetti A, Pelosi G, Uccella S, La Rosa S, Capella C. Microallelotyping defines the monoclonal or the polyclonal origin of mixed and collision endocrine-exocrine tumors of the gut. Lab Invest. 2003;83:963–971. - PubMed